RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that it recently entered into an agreement with LS Associates, a division of LifeSci Advisors, LLC, pursuant to which LSA will provide certain consulting services to the Company, including but not limited to, arranging for the provision of the Company’s Interim Chief Financial Officer. In connection with the Agreement, the Company appointed Richard Narido to serve as Interim Chief Financial Officer of the Company. As Interim Chief Financial Officer, Mr. Narido will serve as the Company’s principal financial officer and principal accounting officer.
“I am pleased to welcome Richard to the team at NRx Pharmaceuticals. He brings great experience and energy to our dynamic company,” said Stephen Willard, Chief Executive Officer of NRx Pharmaceuticals. “Additionally, we are pleased to have immediate access to LSA’s broad team of financial professionals, who will be available to us as needed,” he continued.
Prior to his appointment as the Company’s Interim Chief Financial Officer, Mr. Narido served as the Chief Financial Officer of Lucira Health (“Lucira”) until Pfizer Inc.’s acquisition of Lucira in April 2023. From July 2018 to March 2021, Mr. Narido served in various roles at Assembly Biosciences, Inc., including most recently as Executive Director, Finance, Controllership and Treasury. From June 2014 to June 2018, Mr. Narido served in various roles at Bio-Rad Laboratories, Inc., including as Americas Head of Finance, Global Commercial Operations. Prior to June 2018, Mr. Narido held various finance roles, including Global Head Finance Reporting and Accounting for Novartis Vaccines and Diagnostics and several industry-related positions, including Business Unit Controller for McKesson Corporation. Mr. Narido started his career with PricewaterhouseCoopers’s Financial Audit and Assurance practice. Mr. Narido holds a Bachelor of Science degree from the University of San Francisco and a Master of Science degree from the Pepperdine Graziadio Business School.
The Company also announced that it recently accepted the resignation of Seth Van Voorhees, Ph.D., former Chief Financial Officer of the Company, which was tendered on September 11, 2023, as he has decided to pursue other professional opportunities. His resignation will be effective as of September 30, 2023, in order to facilitate a smooth transition. “We thank Seth for his many contributions to the Company, and we wish him well in his future endeavors,” Mr. Willard commented.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.